Arix Bioscience (ARIX)
ARIX Share PerformanceMore
|52 week high||218.00 17/02/17|
|52 week low||167.50 16/08/17|
|52 week change||0.00 (0.00%)|
|4 week volume||355,257 23/01/18|
Latest News« previous» nextMore
04/01/2018 - 14:15 StockMarketWire
In a letter from the CEO to shareholders, Arix Bioscience has confirmed that during 2017 the Company has directed a sub...
04/01/2018 - 14:00 RNS
RNS Number: 0023B Arix Bioscience Plc 04 January 2018 CEO Letter to Shareholders LONDON, 4 January 2018: As 2018 gets underway, I would like to reflect on Arix Bioscience plc 's ( LSE: ARIX) ("Arix Bioscience" or "Arix" ) first year as a public company and offer some thoughts on the year ahead. We started 2017 with the ambition of building a business with t...
03/01/2018 - 09:46 RNS
RNS Number: 8259A Arix Bioscience Plc 03 January 2018 3 January 2018 Arix Bioscience plc Voting Rights and Capital: Month End Disclosure Pursuant to Disclosure and Transparency Rule 5.6.1: As at 31 December 2017, the issued share capital of Arix Bioscience plc comprised 96,153,090 ordinary shares of 0.00001 each and 49,671 non-voting C Shares of 1.00 each. There ...
22/12/2017 - 07:00 RNS
RNS Number: 1503A Arix Bioscience Plc 22 December 2017 22 December 2017 Arix Bioscience plc Issue of Ordinary Shares, Total Voting Rights and Director/PDMR Shareholding Notifications Arix Bioscience plc (the "Company") announces that it has allotted New Ordinary Shares to two non-executive directors, in accordance with the compensation agreed at their ...
21/12/2017 - 09:40 StockMarketWire
Arix Bioscience has co-led a $30 million series C financing round for Aura Biosciences. Aura is developing a new class of th...
21/12/2017 - 07:00 RNS
RNS Number: 0060A Arix Bioscience Plc 21 December 2017 Arix Bioscience co-leads $30 million financing for Aura Biosciences Funding to advance development of Aura's novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently in Phase 1b/2 study to treat ocular melanoma, an orphan indication LONDON, 21 December 2017: Arix Bioscienc...
04/12/2017 - 07:32 StockMarketWire
Arix Bioscience has led an oversubscribed $30 million series F financing round for Atox Bio. Atox Bio is a late stage clinica...
04/12/2017 - 07:00 RNS
RNS Number: 2209Y Arix Bioscience Plc 04 December 2017 Arix Bioscience leads $30 million financing for Atox Bio Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections Arix achieves target of 12 Group Businesses by the end of 2017, suc...
|Dividend yield||0 %|
Latest discussion posts More
“ Blimey, what's going on? Some negative news out there? IPO oversubscribed and some major holdings - it should be heading the other way. JC ”▼
“Been a bit of a dog so far”▼
“I could not make sense as to what this company is about. Is it similar to Shire which funds R&D through other Biotechs, but it does not have its owns labs?”▼
Codes & Symbols
|Symbols||ARIX, LSE:ARIX, ARIX.L, ARIX:LN, LON:ARIX, XLON:ARIX|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment